This site uses cookies to provide you with a more responsive and personalised service. By using this site you agree to our use of cookies. Please read our cookie notice for more information on the cookies we use and how to delete or block them.

Bookmark Email Print page

Measuring the return from pharmaceutical innovation 2012

Is R&D earning its investment?

  • Measuring the return from pharmaceutical innovation 2012
  • Life Sciences
  • January 2013
  • 846 KB
  • Download Download (PDF)


The cohort of companies comprises the 12 publicly-listed companies reporting the highest absolute research and development (R&D) spend for 2008-09. The late stage pipeline includes those compounds which are either in Phase III development or submitted for approval.

Following feedback on the 2011 report, the methodology had been revisited and enhancements and improvements made to a number of elements including the timing of when pipeline information is used for determining revenue forecasts, allocation of R&D cost between development phases and years, and other items which have a minor impact on margins.

These enhancements have also been applied retrospectively, and the 2010 and 2011 results restated, so that findings from prior years are comparable with 2012.

Stay connected
Get connected
Share your comments